Keywords

• Lorlatinib
• Lorlatinib powder
• 99% Lorlatinib

Quick Details

• ProName: cas 1454846-35-5 99% Lorlatinib powde...
• CasNo: 1454846-35-5
• Molecular Formula: C15H22O5
• Appearance: white
• Application: Artemisia annua is used as antimalaria...
• DeliveryTime: 7-10 days
• PackAge: drum
• Port: Shanghai/Wuhan
• ProductionCapacity: 1000 Kilogram/Day
• Purity: 99
• Storage: room
• LimitNum: 1 Kilogram

Superiority

cas  1454846-35-5 99% Lorlatinib powder

Product Name:    Lorlatinib (PF-06463922)
CAS:    1454846-35-5
MF:    C21H19FN6O2
MW:    406.41
EINECS:    813-704-5

Details

cas  1454846-35-5 99% Lorlatinib powder

Product Name:    Lorlatinib  
CAS:    1454846-35-5
MF:    C21H19FN6O2
MW:    406.41
EINECS:    813-704-5 ..

Lorlatinib  is a new drug under development for the sub-group of advanced non-small cell lung cancerwho are ALK or ROS1 positive and have already undergone gene treatment with drugs thatspecifically targetthis type of cancer.  If marketed it will becomean additional targeted treatment for this sub-group of ALKor ROS1 positive patients.
Lorlatinib acts by inhibiting the ALK and ROS1 receptor tyrosine kinases, with potent activity against a broad spectrum of ALK resistant mutations. By inhibiting ALK phosphorylation and ROS1 activity, lorlatinib inhibits the downstream signalling, thereby inducing the apoptosis process, which results in the inhibition of tumour cells proliferation.

Due to tumor complexity and development of resistance to treatment, disease progression is a challenge in patients with ALK-positive metastatic non-small cell lung cancer (NSCLC). A common site for progression in metastatic NSCLC is the brain.
Lorlatinib was specifically designed to inhibit tumor mutations that drive resistance to other ALK inhibitors and to penetrate the blood brain barrier.